NCT07122661View on ClinicalTrials.gov

STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)

Active, not recruitingOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Respiratory Syncytial Virus (RSV)Respiratory Syncytial VirusLower Respiratory Tract DiseaseRespiratory Tract DiseasesAcute Respiratory Illness (ARI)
Interventions
BIOLOGICAL

ABRYSVO

This is a non-interventional retrospective study; therefore, ABRYSVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

The Kids Research Institute Australia on behalf of the Centre for Child Health Research, University of Western Australia

UNKNOWN

lead

Pfizer

INDUSTRY